Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Ensartinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
- 15 Aug 2023 Status changed from recruiting to completed.
- 13 Sep 2022 Results (n=482) of a Pop PK model development analysis from four clinical trials: BTP-28311, X396-CLI-101, X396-CLI-301, and BTP-42322 presented at the 47th European Society for Medical Oncology Congress
- 22 Nov 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.